drugset / Trial / NCT07650825
OVV-01 Intravenous and Intratumoral Injection Combined With AK112 for the Treatment of Advanced Solid Tumors
Phase 1
Not yet recruiting
30 enrolled
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is an open-label, multiple-route-of-administration dose-escalation clinical trial designed to evaluate the safety and preliminary efficacy of OVV-01 injection administered intravenously or intravenously plus intratumorally, either as monotherapy or in combination with AK112 injection, in subjects with advanced solid tumors.
Timeline
- Start
- 2026-08-01
- Primary completion
- 2027-01-31
- Completion
- 2027-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ivonescimab | Monoclonal antibody | — | — |
| Subject | OVV-01 | Unknown | — | Intravenous |